Positron Emission Tomography to Assess the Effect of Camzyos on Ischaemia in HOCM: PEACH Trial
The PEACH Trial is exploring how Camzyos (Mavacamten), a medicine for a heart condition called Hypertrophic Obstructive Cardiomyopathy (HOCM), affects blood flow to the heart muscle. People with HOCM often have thickened heart muscle, which can block blood flow and lead to chest pain and breathlessness. While Camzyos is known to help with this blockage, we don't fully understand its effect on oxygen supply to the heart. This study uses special scans, called PET-CT, to check blood flow before and after people start taking Camzyos as part of their usual care. The goal is to see if Camzyos improves this blood flow, which could help doctors better manage HOCM.
At a glance
What is this study about?
If you have a heart condition called Hypertrophic Obstructive Cardiomyopathy, or HOCM, you might know that it causes the muscle of your heart to thicken. This thickening can make it harder for blood to leave your heart, which doctors call a 'left ventricular outflow tract obstruction'. Many people with HOCM also experience chest pain and feel out of breath because their heart muscle isn't getting enough oxygen, even if their main arteries aren't blocked.
A new medicine called Camzyos (Mavacamten) has been shown to help with the blood flow obstruction in people with HOCM. However, doctors are still learning about how this medicine affects the oxygen supply to the heart muscle itself. This study, called the PEACH Trial, aims to find out if Camzyos helps to improve blood flow and oxygen delivery to the heart muscle in people with HOCM.
To do this, researchers will use a special type of scan called a PET-CT scan. This scan helps them see how much blood is flowing to your heart muscle. You would have one scan when you start taking Camzyos as part of your usual treatment, and then another one about 12 months later. Camzyos will be prescribed by your usual doctor, and this study won't affect how you receive your medication. The results of these scans will help doctors understand more about how Camzyos works and could lead to better tailored treatments for HOCM patients in the future.
Key takeaways
- This study looks at how Camzyos affects blood flow to the heart in people with HOCM.
- It uses special PET-CT scans to measure changes in heart blood flow.
- You would already be starting Camzyos as part of your normal medical care.
- Participation involves two PET-CT scans over about a year.
- The findings could help improve future treatments for HOCM.
Who may be eligible?
This study is looking for adults aged 18 or older who have been diagnosed with Hypertrophic Obstructive Cardiomyopathy (HOCM). You would need to have symptoms like chest pain or shortness of breath, which suggest your heart muscle isn't getting enough oxygen. Importantly, you would also need to be a candidate for starting treatment with Camzyos (Mavacamten) as part of your normal heart care, as decided by your specialist heart doctor.
You wouldn't be able to join the study if you have blockages in your main heart arteries that are causing your oxygen supply issues. If your doctors find clear blockages leading to your symptoms after an initial scan, you wouldn't be suitable for this research. However, if your scans show that your oxygen problems aren't due to blocked main arteries, then your doctor might discuss this study with you.
- Are you 18 years old or older?
- Do you have a diagnosis of HOCM?
- Do you experience chest pain or breathlessness related to your heart?
- Are you about to start taking Camzyos (Mavacamten) as prescribed by your heart specialist?
- Are your heart symptoms not caused by blockages in your main heart arteries?
This is a guide only — the research team will confirm whether you can take part.
What does participation involve?
If you decide to take part in this study, you would primarily have two special heart scans called PET-CT scans. The first scan would happen when you start taking Camzyos (Mavacamten) as part of your regular heart treatment. If you've recently had a similar scan that showed certain findings, that scan might count as your first one. About 12 months later, you would have a second PET-CT scan. This second scan is purely for the research study.
It's very important to know that the study does not provide the Camzyos medication; you will receive it from your own doctor as part of your routine care. The study is simply looking at the effects of the medication once you've started taking it. There are no extra hospital visits or ongoing assessments specifically for the study beyond these two scans. The total duration of your active involvement in the study would be about 12 months, covering the period between your two scans.
Potential risks and benefits
Locations (1)
- Manchester University NHS Foundation TrustManchester, United Kingdom· Recruiting
Common questions
What is HOCM?
HOCM stands for Hypertrophic Obstructive Cardiomyopathy. It's a condition where part of your heart muscle becomes thicker than normal, which can make it harder for blood to leave your heart.
What is Camzyos (Mavacamten)?
Camzyos is a medicine used to treat HOCM by helping to reduce the obstruction of blood flow from the heart.
What is a PET-CT scan?
It's a special type of scan that helps doctors see blood flow in your heart muscle and understand if your heart is getting enough oxygen.
Will the study pay for my Camzyos medication?
No, the study does not provide or pay for Camzyos. You will receive your medication from your own doctor as part of your usual care.
Who is running this study?
The study is sponsored by the University of Manchester and funded by Bristol Myers Squibb.
How to find out more
Tamara Naneishvili, MBBS, MRCP (UK)
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.